US Weight-Loss Injection Recall Raises Sterility Concerns, but Mounjaro and Zepbound Are Unaffected
Latest news on WhatsApp أجدد الأخبار على واتساب
A voluntary recall of compounded weight-loss injections in the United States has raised fresh concerns about the safety of medications prepared outside the standard drug approval process. North Carolina-based Apothecary Pharma has recalled certain tirzepatide injections because their sterility could not be assured. The recall does not affect the FDA-approved brand-name medicines Mounjaro and Zepbound.
The company initiated the recall on September 24, 2026, and the US Food and Drug Administration classified it as Class II on October 8. The action attracted renewed attention on October 20 as news organizations reported the affected products and the company's regulatory history. A Class II recall indicates that exposure could cause temporary or medically reversible health effects, while the likelihood of serious harm is considered remote.
The recalled product is Apothecary Pharma Tirzepatide Injection, containing 18 mg/mL in 4 mL multidose vials, identified by NDC 85091-001-18. The recall record lists 22 affected lot numbers under recall number D-0036-2027. Some of the injections were supplied through telehealth providers, meaning patients may have received them from intermediaries rather than directly from the manufacturer.
The recall follows an FDA warning letter issued to Apothecary Pharma in December 2025 after inspectors identified serious shortcomings in sterile drug production. The findings included inadequate sanitation practices, problems maintaining appropriate airflow around exposed medications and equipment conditions that could increase contamination risks. The agency concluded that the company's practices had not adequately protected products intended to be sterile.
Tirzepatide is the active ingredient in Mounjaro, approved for type 2 diabetes, and Zepbound, approved for weight management. However, compounded versions are not FDA-approved and do not undergo the same premarket evaluation for safety, effectiveness and quality. The regulator warns that sharing an active ingredient with an approved medicine does not make a compounded preparation equivalent to that medicine.
The recall also includes an Apothecary Pharma NAD+ injectable product over similar sterility concerns. Authorities have not established that every recalled vial was contaminated; the stated concern is that sterility cannot be reliably assured.
Patients who may have received the affected medication are advised to compare the manufacturer and lot number on their vial with the official recall record and seek guidance from their pharmacist or prescribing clinician before their next dose. Patients using tirzepatide for diabetes should not make changes to their treatment without appropriate medical advice
